To evaluate the effectiveness of a deintensified 60-Gy radiotherapy regimen in patients with HPV-associated oropharyngeal carcinoma, focusing on patient outcomes.
Key Findings:
5-year locoregional recurrence rate was 3.4% (95% CI, 1.1%–5.8%).
Progression-free survival was 86.5% (95% CI, 82.1%–91.0%), and overall survival was 92.4% (95% CI, 89.0%–96.0%).
Distant recurrence occurred in 7.3% of patients at 5 years.
Among lower-risk patients treated with radiotherapy alone, 5-year progression-free survival was 93.8%.
Interpretation:
The study suggests that modest dose deintensification of 60-Gy radiotherapy can achieve high rates of locoregional control in selected patients with HPV-associated oropharyngeal carcinoma, indicating potential for future research.
Limitations:
Single-arm design without a standard-dose comparator group, which may affect the robustness of the findings.
Treatment delivery within a specialized academic system may limit generalizability to broader cooperative-group practice settings.
Long-term toxicity and quality-of-life outcomes were not fully evaluated, which is crucial for comprehensive understanding.
Conclusion:
Findings support ongoing discussions about deintensification in HPV-associated OPC but do not change the current standard of care; further studies are needed.
Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.
